cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Manual Therapy Combined With an Exercise Programme VS Combined Electrotherapy on Football Players With Adductor Tendinopathy

Background: Groin pain associated with adductor tendinopathy is the second cause of muscle pathology in a football player (20%), so a good treatment taking into account both internal and external factors that may influence the pathology of our patient, would be the key to an improvement in the symptoms he may have. Material and methods: Firstly, the pain threshold is measured by performing the Copenhagen compression test, and in a palpation at the proximal level of the adductors, the hip joint range (ROM) is measured and the HAGOS questionnaire is passed. Then, a sample of 20 participants (N = 20) is selected and randomly divided into two groups, a control group of 10 participants (n = 10), with a treatment based on electrotherapy combined with an exercise programme; and an experimental group of 10 participants (n = 10) with a treatment based on manual therapy combined with an exercise programme. Finally, they performed all measurements.


Eligibility Criteria:
Inclusion Criteria:

* Age range between 15 and 30 years old.
* Third division and third year national youth football players.
* Males.
* Average of 3 training sessions and 1 match per week.
* Pain when performing the Copenhagen test or Squeeze test for 5 seconds (s).
* Pain on palpation of the proximal insertion of the adductors.

Exclusion Criteria:

* Players over 30 years of age and under 15 years of age.
* Players with previous adductor surgery.
* Players with inguinal hernia.
* Players with signs or symptoms of urinary or genital pathology.
* Players unable to attend study treatment sessions.
* Players on medication during treatment.
* Players who are undergoing other treatment for groin pathology or have had previous treatment of less than one month.

previous treatment of less than one month.
Analysis of Retinal Vessel Pulsations With Electrocardiographic Gating

Analysis of Retinal Vessel Analyzer (RVA) recordings of retinal vessel pulsations, and putting them in context of intraocular pressure (IOP) pulsations by means of electrocardiographic (ECG) gating, in order to determine the lead source for pulsations of retinal veins.

Rationale / Objective is to construct the retinal vessels wall pulsation cycle using an electrocardiographic gating, and to analyse it in comparison with an analogue intraocular pressure (IOP) cycle.

Based on the amplitude and on the phase shift of pulsations of retinal vessel wall, the goal is to identify a lead source of the retinal venous pulsations (IOP pulsations, or alternative sources, e.g. cerebrospinal fluid pulsations).

Subjects will be recruited from the environment of the master thesis medical students, colleagues and friends and the informed consent will be handed to them personally. Exclusion criteria will be addressed. One random eye per subject will be selected. On the study day, first the mydriasis drops - phenylephrine + tropicamide - will be applied, then ECG electrodes attached; 20 minutes after the mydriasis drops, the first set of measurements will be performed: RVA recording with ECG gating, and Pascal Dynamic Contour Tonometry (DCT) recording with ECG gating. Ten minutes after this measurements, 100% oxygen 5 liters/min through nasal cannula will be applied for 2 minutes and then the same measurements repeated. Approximate time needed for the whole run - around 60 minutes per subject, including (dis)mounting the ECG electrodes and the mydriasis time.

Eligibility Criteria:
Inclusion Criteria:

-

Exclusion Criteria:

Known ophthalmological disease, in particular vascular disease.
Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage

As an alternative biomarker of intrahepatic covalently closed circular DNA(cccDNA) transcriptional activity, hepatitis B virus(HBV)RNA may evolve during long-lasting virus-host interactionsduring chronic hepatitis B viral infection.The distribution pattern of serum HBV RNA levels in the natural course of chronic HBV infection remains unclear. Furthermore,serum HBV RNA was associated with response to NAs. So it may be another clinical surrogate marker for intrahepatic cccDNA level after long-term NAs treatment and be used to monitor NAs therapy. The aim of this study was to evaluate thelevels of HBV RNA during the natural courseof CHB and the role in distinguishingthe natural phases of HBV infection and to investigate whether serum HBV RNA level at the end of long-term NAs treatment had a similar or better predict effect on off-therapy relapse than serum HBsAg titer.


Eligibility Criteria:
Inclusion Criteria:

* 18 to 70 years old,
* no gender restriction,
* serum HBsAg positive than 6 months,
* can understand and sign informed consent,
* good compliance.

Exclusion Criteria:

* coinfected with other hepatotropic virus such as hepatitis C virus,hepatitis D -virus,hepatitis E and hepatitis A etc;
* coinfected with HIV,
* markers such as ceruloplasmin, anti-nuclear antibodies and anti-mitochondrial antibodies for co-existent autoimmune and metabolic liver diseases were positive,
* with hepatocellular carcinoma(HCC)
* with uncontrollable extrehepatic disease,
* received glucocorticoid or other immune inhibitor therapy,
* pregnancy.
Efficacy and Safety Study of Aspirin for the Prevention of Renal Artery Stenosis in Renal Transplantation Recipients

The anastomotic and peripheral stenosis of the transplanted kidney artery is one of the most important causes of graft failure in renal transplantation. The injury of vascular intima and the formation of microthrombosis may play a significant role in the stenosis of transplanted renal artery of recipients. Inhibiting this process with aspirin may protects against the stenosis of transplanted renal artery.

This is a prospective, randomized, controlled, clinical trial to investigate the efficacy and safety of prevention of renal artery stenosis in recipients.


Eligibility Criteria:
Inclusion Criteria:

1. The patients with the first renal transplantation were stable;
2. Age ≥ 18 years old;
3. Other anticoagulants and non steroidal anti-inflammatory drugs were not taken at the same time;
4. In the past 3 months, there was no acute cardiovascular and cerebrovascular disease or infection;
5. The rejection of acute and chronic renal transplantation was excluded;
6. The thrombus formation of transplanted kidney was excluded.

Exclusion Criteria:

1. Allergic or intolerable to aspirin;
2. Previous transplant history;
3. Age \< 18;
4. Take other anticoagulants or non steroidal anti-inflammatory drugs at the same time;
5. History of active gastrointestinal bleeding or severe peptic ulcer;
6. Patients with bleeding tendency or severe liver disease;
7. Cerebral hemorrhage, cerebral infarction or acute infection occurred within 3 months;
8. Acute and chronic rejection;
9. Thrombus formation of transplanted renal vessels;
10. Any condition that increases the risk of adverse events or discontinuation.
Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease

In this study, it is aimed to compare the effects of cognitive exercises applied on long-term internet environment to the cognitive level of patients who received donepezil, memantine or donepezil / memantin combination therapy.


Eligibility Criteria:
Inclusion Criteria:

* Patients between 55-90 years old who were diagnosed with Alzheimer's Dementia and had no history of cerebrovascular disease during the last 6 months,
* Patients without other neurodegenerative diseases and secondary dementia diagnoses,
* Patients with MOCA score of between 13-18,
* Patients with at least primary school graduation,
* Patients who have had no CNS disease including trauma in the last year,
* Patients without a diagnosis of psychiatric disease,
* Patients with a tablet or PC with an internet connection,
* Patients agreeing to perform BEYNEX daily activity at least 5 times per week,
* Patients signing informed consent form.

Exclusion Criteria:

* Patients who have hypersensitivity to study working drugs,
* Psychotic patients,
* Disabled patients with orthopedic dominant extremity,
* Patients with ICU follow-up due to trauma in the last 6 months,
* Patients with severe visual impairment or eye surgery,
* Patients who refuse to sign the informed consent form.
Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

The purpose of this study is to assess the safety and effectiveness of DTG use in HIV positive pregnant women. This is a 3-year multi-site prospective observational study. Approximately, 250 HIV positive pregnant women from potential European AIDS Treatment Network (NEAT ID) sites across Europe will be enrolled. The enrollment period will be over 2 years with a follow-up period of 1 year for outcomes. The data collected will be that obtained during routine standard of care assessments; and the subjects will not undergo any interventional study procedures.


Eligibility Criteria:
Inclusion Criteria:

* HIV positive pregnant women aged 18 years and over on DTG
* With no maternal or birth outcomes yet
* Subjects are able and willing to provide written informed consent and comply with any safety reporting requirements.

Exclusion Criteria:

-
Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals

To compare efficacy and adverse effects of fractional CO2 laser of acne scars treatment with 1 versus 3 months intervals

Change in scar texture evaluated by blinded evalutaions. Appearance of erythema, oedema, pigmentation, infection after treatment

Eligibility Criteria:
Inclusion Criteria:

* Have Fitzpatrick skin type I-III. (•Are male or female.
* Are between 18 and 60 years of age.
* Mild to severe acne scarring.
* Are able to read, understand, and sign the Informed Consent.
* Are willing and able to comply with all follow-up requirements -

Exclusion Criteria:

* Have had active localized or systemic infections within 6 months of enrollment
* Have compromised ability for wound healing, such as: malnutrition, oral steroid use, history of collagen vascular disease (e.g. lupus, scleroderma, history of keloid formation (raised and thickened scars), atrophic dermatitis (extreme skin irritation or itchiness) or immunologic abnormalities such as vitiligo (white patches of skin due to loss of pigment)
* Have been treated with lasers, chemical procedures, or other cosmetic procedures on the area to be treated within 6 months of enrollment
* Pregnancy
Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD)leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer)in the cells of the monocyte-macrophage system.

This is the first trial to utilize a recombinant active form of lysosomal enzyme, glucocerebrosidase, (human prGCD)which is expressed and purified in a bioreactor system from transformed carrot plant root cell line.


Eligibility Criteria:
Inclusion Criteria:

1. Healthy male or female between 18 and 45 years of age.
2. Female subjects must agree to use a medically acceptable method of contraception at all times during the study and must have a negative serum pregnancy test at baseline and during the study period.
3. Females of child-bearing potential must be non-pregnant and not lactating and using adequate birth control such as oral contraceptives.
4. Negative laboratory tests for HIV, HBsAg or HCV.
5. Naive to any previous recombinant protein therapy.
6. Provide written informed consent.
7. Have the ability to understand the requirements of the study and to comply with the study protocol and dosing regimen.

Exclusion Criteria:

1. Have clinical evidence of any active significant disease that could potentially compromise the ability of the investigator to evaluate or interpret the effects of the study treatment on safety assessment and thus increase the risk to the subject to unacceptable levels.
2. Are pregnant or nursing.
3. Presence of any acute or chronic diseases.
4. Have a history of any allergies.
5. Have been exposed to long-term steroid treatment.
6. Had a minor operation in the last 6 months.
7. Have ever been exposed to any previous recombinant protein therapy.
8. Have received immuno-suppressive treatment.
9. Have a positive HIV, HBsAG and HCV laboratory result.
10. Use any medication other than vitamins or oral contraceptives (for female).
11. Have participated in another clinical trial during the previous 3 months
12. Have history of alcohol or drug abuse.
13. Are considered by the Investigator to be unsuitable candidate for this study.
Impact of Maternal Supplementation With Dual Megadose of Vitamin A

The purpose of this study is to evaluate the effect of maternal supplementation with 400,000 IU of oral retinol palmitate in the post-partum, the nutritional situation of the binomial mother-child, on growth and morbidity of children in breastfeeding in the first six months of life.

The effect will be assessed by the milk and blood.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant low-risk obstetric

Exclusion Criteria:

* Premature birth
* Newborn babies with birth defects and / or other serious diseases
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults


Eligibility Criteria:
Inclusion Criteria:

1. Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
2. Age: 18-75 years old (including boundary values of 18 and 75);
3. Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity

Exclusion Criteria:

The subject's previous history of anti-tumor treatment meets one of the following conditions:

1. Individuals who have previously received bevacizumab
2. Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
3. Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

The purpose of this study is to assess the effect of Rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH).

The total duration per patient will be approximately 28 months including a 24-month double-blind treatment period.

Eligibility Criteria:
Inclusion Criteria:

* Patients with diagnosis of NASH

Exclusion Criteria:

* Excessive alcohol use
* Presence of diabetes mellitus
* Other chronic liver disease
* Previous or current hepatocellular carcinoma
* Use of medication known to cause steatosis
* Previous bariatric surgery
* Pregnancy or breastfeeding
* Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Is Ultrasound-Guided Steroid Injection Less Effective in Carpal Tunnel Syndrome Patients with Bifid Median Nerve?

The aim of this study is to evaluate the short-term efficacy of ultrasound-guided corticosteroid injection in patients with and without bifid median nerve.

Twenty-five patients with bifid median nerve and twenty-five patients without bifid median nerve, aged 18-65, who applied to the Physical Therapy and Rehabilitation outpatient clinic at Beylikdüzü State Hospital, diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies, and who received ultrasound-guided corticosteroid injection, will be included in our study. Patients identified as having a bifid median nerve during the injection will be noted and invited for a follow-up at the 1st month to assess their pain and functional status. The same follow-up visit will be conducted for an equal number of age- and gender-matched patients without bifid median nerve who received the injection. At the end of the study, the 1-month efficacy of the injection in both groups will be evaluated. Patients who agree to participate in the study will be asked to complete the Visual Analog Scale (VAS), the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ), and the Quick Disabilities of the Arm, Shoulder, and Hand Questionnaire (Quick-DASH) before the injection. They will then be invited for a follow-up visit at the 1st month, where the VAS, BCTQ, and Quick-DASH will be administered again.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-65.
* Diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies conducted within the last 6 months.
* Scheduled for ultrasound-guided corticosteroid injection.
* Patients who have agreed to participate in the study.

Exclusion Criteria:

* Diagnosis of any other condition that could cause neuropathic symptoms, such as polyneuropathy, brachial plexopathy, or thoracic outlet syndrome.
* Previous history of injection or surgery for carpal tunnel syndrome
* Patients who refuse to participate in the study.
SMART Technology to Promote Heart Health in Midlife Adults

This study aims to increase weekly minutes of moderate-to-vigorous physical activity and improve sleep quality in a sample of mid-life adults between ages 50 and 64 years.

This 2-year study will develop, test, and refine a cloud-based feedback system, and evaluate the impact of a 3 month randomized controlled feasibility pilot intervention - the Bio-behavioral systems to Motivate and Reinforce Heart Health trial (Be SMART) on changes in moderate-to-vigorous physical activity (MVPA) and sleep among mid-life adults between ages 50 and 64 years.

Aim 1 will examine the acceptability of the Be SMART system. We will conduct a 6-week proof- of-concept study in 10 mid-life adults to specifically examine recruitment plausibility, adherence and attrition rates, satisfaction, and implementation fidelity.

Aim 2 will quantify the impact of the Be SMART intervention (n=30) on changes in MVPA and sleep metrics compared to a Fitbit-only condition (n=30) among mid-life adults (N=60). Hypothesis 2a: At 3 months, participants in the Be SMART condition will show significantly greater weekly minutes of MVPA compared to the Fitbit-only condition, controlling for baseline. Hypothesis 2b: At 3 months, participants in the Be SMART condition will be significantly more likely to report adequate sleep duration, shorter sleep latency, and earlier sleep timing, compared to the Fitbit-only condition, controlling for baseline.

Aim 3 will explore the extent to which changes in MVPA and sleep metrics impact blood pressure changes among mid-life adults (N=60). Secondly, this study will quantify the extent to which Be SMART participants (n=30) achieve their weekly goals and if goal achievement impacts changes in blood pressure at 3 months. Hypothesis 3a: Changes in MVPA and sleep metrics will be related to changes in blood pressure. Hypothesis 3b, the degree of goal achievement will be related to changes in blood pressure.

Eligibility Criteria:
Inclusion Criteria:

* 50-64 years of age
* Prehypertensive (120/80 mmHg - 139/89 mmHg) or stage 1 hypertensive (140/90 mmHg - 159/99 mmHg)
* Physically inactive (\<100 minutes of MVPA in the previous week)
* Report insufficient sleep duration (\<6 hours/night on \>7 nights in the past month)
* Own a smartphone
* Non-smoker
* No signs or symptoms of chronic disease
* Have no chronic pain
* Have no major depressive disorder, general anxiety disorder, or sleep disorder
* Do not work alternating day-night shifts
* Medical clearance obtained from individual's physician

Exclusion Criteria:

* Younger than 50 years; older than 64 years
* Not prehypertensive or blood pressure is \>159/99 mmHg
* Physically active (\>100 min of MVPA in the previous week)
* Report sufficient sleep duration (\>6 hours/night on 7 or more nights in the past month)
* Does not own a smartphone
* Current smoker
* Report signs/symptoms of chronic disease
* Experiences chronic pain
* Have major depressive disorder, general anxiety disorder, or sleep disorder
* Works alternating day and night shifts
* Medical clearance not obtained from individual's physician
Validation of the Spanish Version of the Conceptualization of Pain Questionnaire

The goal of this observational study is to develop a questionnaire to assess a child's concept of pain and to evaluate its psychometric properties in schoolchildren aged 8-17 years. The main question\[s\] it aims to answer are:

* Validate to Spanish language the Conceptualization of Pain Questionnaire to assess a child's concept of pain.
* Conduct an analysis to evaluate its psychometric properties. Participants will respond a questionnaire of 15 items and asks respondents to respond if they believe the items/statements to be true or false, although they are allowed to respond undecided.

The inclusion criteria were: to be able to read and write in Spanish language and excluded if they suffered from an intellectual disability that, according to the teachers, could interfere with their participation in the study procedures.

The main outcome was: The Conceptualization of Pain Questionnaire - Spanish version.

Eligibility Criteria:
Inclusion Criteria:

* Were able to read and write in Spanish

Exclusion Criteria:

* If they suffered from an intellectual disability that, according to the teachers, could interfere with their participation in the study procedures.